Objectives: This study evaluated the prevalence and correlates of aberrant drug-taking behaviors in two populations: patients with HIVrelated pain and a history of substance abuse (n = 73) and patients with cancer pain and no history of substance abuse (n = 100).
F ew investigations have illuminated the relationships among undertreated pain, drug abuse history, and the aberrant use of prescribed and street drugs in medically ill populations. Prior studies suggest that drug abuse in the setting of pain management may be uncommon but not rare, may have numerous psychosocial and pain-related correlates, [1] [2] [3] [4] and may significantly predict undertreament of pain in both cancer and AIDS populations. 5, 6 These limited data underscore the clinical importance of drug abuse in the medically ill and highlight the need for studies to further define its epidemiology and clarify its relationships to addiction, the underlying disease, acute and chronic pain, and a broad range of psychological and social factors. 7 Our group has been interested in articulating conceptual and assessment issues in substance abuse in medically ill populations with pain, as have a few other researchers. [1] [2] [3] In our efforts to investigate the issues associated with identifying and assessing potentially aberrant drug-taking behaviors in cancer and chronic pain patients, we have conducted several studies using approaches such as chart reviews, structured interviews, and brief surveys. 4 Potential drug abuse in the clinical setting takes the form of highly variable aberrant drug-related behaviors. These behaviors must be discerned by the clinician and then interpreted appropriately to yield a clinically meaningful understanding of the factors that contribute to their appearance in the clinical setting and the strategies that must be implemented to regain control over the therapy 7 (Fig. 1 ). The process of interpretation and treatment would be facilitated by an understanding of the prevalence and correlates of aberrant drug-related behaviors in various populations. To acquire this information, we developed a structured interview that elicits self-reports of medication use, past and present drug abuse, beliefs concerning the risk of addiction during pain treatment, and aberrant drugtaking behaviors and attitudes in medically ill populations. 8 In the present study, this interview was used to compare the prevalence, nature, and correlates of aberrant drug-taking behaviors in two populations that diverge in the base rates of addiction and undertreatment: (1) patients with HIV-related pain and a history of substance abuse and (2) patients with cancer pain and no history of substance abuse. This comparison may illustrate the range of relevant behaviors and their correlates encountered in the clinical setting. This study was undertaken to examine rates of aberrant drug-related behavior in cancer and substance-abusing AIDS patients with pain and their predictors, given the myriad differences between these two groups (ie, age, history of substance abuse, likelihood of adequate pain therapy).
METHOD
The study was approved by the Western Institutional Review Board. All patients provided informed consent prior to participation. Subjects were recruited from two primary sources. A convenience sample of patients with AIDS pain and a history of substance abuse were recruited through the Damien Center in Indianapolis and its outreach network throughout seven contiguous counties. A second convenience sample of cancer patients with pain was recruited through the Community Cancer Care network, consisting of 32 community-based cancer programs. Subjects were recruited over a 2-year period.
All patients were adults, English-speaking, and capable of completing written questionnaires. Patients for the AIDS sample had to have a documented diagnosis associated with chronic pain, opioid treatment, endorsement of pain on a screening item, and a diagnosis of current or past substance use disorder (SUD) based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 9 The SUD diagnosis was established on the basis of the Structured Clinical Interview for DSM-IV (SCID). The cancer patients were included if they had chronic pain described in the medical record, endorsement of pain on a screening item, and no evidence of a current SUD according to DSM-IV criteria.
After informed consent was obtained, eligible patients were interviewed to gather baseline information on demographics, medical condition, and medications. Subjects were then administered a questionnaire packet by one of the investigators, which was followed by the structured interview. Patients unable to complete the questionnaires independently were administered the instruments by the interviewer. Completion of the questionnaires and interview required approximately 60 minutes. Patients were then debriefed and compensated $25. Patients who declined to participate in the interview were asked some basic questions about their refusal.
Study Instruments
Instruments were chosen to measure demographic and illness-related variables: pain, symptom and psychological distress, and social desirability. Drug-taking behaviors and attitudes were elicited through the structured interview. 
Demographic and Medical History Questionnaire
Patients were asked to provide basic demographic and medical data (eg, age, race, education, occupation, AIDS staging information, cancer site and stage, duration of illness). To confirm the SUD diagnosis, an abbreviated version of the substance abuse and dependence sections of the SCID was administered by researchers trained to provide reliable psychiatric diagnoses of SUD. Pain-related data included an assessment of severity during the week prior to the interview.
Pain Management Index
The Pain Management Index (PMI) was initially designed for patients being treated for cancer-related pain to address a pressing need in the literature to quantify the adequacy of pain management. 10 This index is not a ''measure'' in the psychometric sense and therefore has not undergone typical reliability and validity study. Nevertheless, because the need in the literature for such an index is so great, it has been used in a series of studies with consistent results of 50% to 70% undertreatment of pain for patients with cancer or AIDS. [11] [12] [13] The PMI was computed using the worst pain rating and the most potent analgesic ordered, according to the guidelines of the World Health Organization and the Agency for Health Care Policy Research. 14, 15 In this methodology, the 1-to-10 pain intensity scale is collapsed into three categories, with 1 being mild (1-3), 2 moderate (4-7), and 3 severe (8-10). 16 The index is rated on a scale of -3 (greatest discordance between reported pain and prescribed analgesic) to +3 (greatest concordance between reported pain and prescribed analgesic). The PMI is conservative in that it fails to consider the dose of drug prescribed and the use of adjuvant agents. Of particular importance to the present study, this problem may be amplified in substance abusers. Such patients, because of their tolerance built up over years of misuse of opioids, are more likely than other patients to be underdosed when undergoing opioid therapy for pain. Furthermore, the PMI does not account for prescribing of adjuvant analgesics and their efficacy. This is a particularly important point in HIV pain management, where there is a high frequency of neuropathic pain syndromes. Of note, Breitbart et al 12 found that while 40% of the pain syndromes described were neuropathic in etiology, only 6% of patients were receiving adjuvant analgesics. Thus, while there are problems applying the PMI to HIV samples, it is highly likely that patients categorized as being undertreated with opioids are in fact undertreated in general.
Brief Symptom Inventory (BSI)
The BSI, a 53-item version of the SCL-90, is a reliable and valid measure of psychiatric symptoms that has been used extensively in the medically ill, including cancer patients and HIV-infected individuals. [17] [18] [19] [20] For the purposes of this study, the Depression and Generalized Anxiety subscales, as well as the Global Severity Index, were used for data analysis.
Brief Pain Inventory (BPI)
The BPI includes numeric rating scales (0-10) for pain intensity ''now'' and at its ''worst,'' ''least,'' and ''average''during the past week. Other numeric scales assess the extent to which pain interferes with general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. The BPI is reliable and valid 6, 21 and has been used widely in cancer pain research and several studies of pain in AIDS. 12, 22, 23 Memorial Symptom Assessment Scale (MSAS)
The MSAS records the prevalence of 33 symptoms during the past week and rates each according to frequency, intensity, or associated distress. 24 For the purposes of this study, a validated subscale of 10 common physical and psychological symptoms (the Global Distress Index [GDI]) was used as a measure of overall symptom distress.
Marlowe Crowne Social Desirability Scale (MCSDS)
The MCSDS has been widely used to assess so-called social desirability or the ''faking good'' response set. 25 This response set reflects a need to be perceived in a favorable light and is especially important when the traits being assessed may be socially undesirable (ie, aberrant drug-taking). The scale consists of 33 true/false items that are culturally sanctioned and approved but have an improbable chance of occurrence, such as ''I'm always willing to admit it when I make a mistake'' (T) or ''I am sometimes irritated by people who ask favors of me'' (F).
Drug-Taking Behaviors Interview
Based on the findings of our pilot work, 4 open-ended questions elicited information pertaining to use of street drugs for symptom control, diversion of prescribed drugs for symptom control, use of prescribed medications for nonprescribed purposes, and other more common but less dramatic aberrant behaviors (eg, unsanctioned dose escalation).
Data Analysis
The demographics and medical characteristics of the AIDS sample with pain and substance abuse and cancer sample were tabulated. The number of aberrant behaviors endorsed was tabulated and summed to create a total number of these behaviors per subject. Between-group differences in frequencies of these categories of behaviors and in the scores on various study measures were evaluated through chi-square analyses and analysis of variance (ANOVA). Chi-square analyses also were used to examine group differences in terms of scores on the PMI (receiving analgesia consistent with accepted guidelines or not). A series of Pearson correlations were generated to examine the associations among all of the symptom distress and aberrant drug-taking variables. Multiple regression analyses used the aberrant drug-taking items as dependent variables and examined the independent association of significantly correlated (zero-order correlations) items pertaining to demographics, pain, and physical and psychological symptom distress.
RESULTS
A total of 173 patients (AIDS patients with pain and substance abuse, n = 73, and cancer patients, n = 100) completed the study ( Table 1 ). The sample comprised 101 men (58.4%) and 72 women (41.6%) and had a mean age of 51.6 q 2006 Lippincott Williams & Wilkins years (SD = 15.2). Most were Caucasian (n = 118, 68.2%) or African-American (n = 50, 28.9%). Sixty-five subjects were married (37.8%), 45 were single (26.2%), 36 were divorced (20.9%), 21 were widowed (12.2%), and 5 were separated (2.9%). The basic demographic variables for the cancer and AIDS subgroups are also listed in Table 1 .
There were many differences between the AIDS and cancer samples. The AIDS patients with pain and substance abuse were significantly younger (t 1, 170 = 32.31, P , 0.001), less educated (x 2 = 16.56, P , 0.05), and more unemployed (x 2 = 46.52, P , 0.001) than the cancer patients. The AIDS sample had more men (x 2 = 40.52, P , 0.001), minorities (x 2 = 35.42, P , 0.001), and single people (x 2 = 81.16, P , 0.001). The AIDS patients also were more likely to report current (x 2 = 43.42, P , 0.001) and past (x 2 = 36.64, P , 0.001) psychiatric problems.
Although cancer patients with recognized SUDs were excluded from the study, results of the substance abuse and dependence sections of the SCID interview revealed that three (3%) met criteria for mixed alcohol dependence, with two of these patients also meeting criteria for opioid dependence (2%). Moreover, the separate Drug-Taking Behaviors Interview identified 13 (13%) cancer patients who reported a prior alcohol problem, 1 (1%) who reported a suicide attempt, 5 (5%) who broadly reported a past drug problem, and 25 (25%) who reported a family history of alcoholism.
In the AIDS sample with pain and substance abuse, the SCID showed that 65 (89%) subjects met the criteria for a current SUD (all had at least a past history to qualify for the study), which was most likely to be alcohol (n = 44, 60.3%), cocaine (n = 28, 38.4%), cannabis (n = 12, 16.4%), or opioid (n = 6, 8.2%) dependence (not mutually exclusive). The Drug-Taking Behaviors Interview further identified 26 (35.6%) who acknowledged a current alcohol problem, 56 (76.7%) who acknowledged a past alcohol problem, and 50 (68.5%) who stated that they had a family history of alcoholism. Also, the interview identified 20 (27.4%) who reported a current drug problem, 52 (71.2%) who reported a past drug problem, and 40 (54.8%) who had attended drug treatment in the past. Finally, a total of 22 (30.1%) reported a prior suicide attempt.
A series of one-way ANOVAs were calculated comparing the cancer and AIDS subgroups on the study measures ( Table 2 ). The AIDS subgroup with pain and substance abuse scored significantly higher on the MCSDS (F 1, 169 = 27.18, P , 0.001), indicating a greater propensity to answer in a socially desirable fashion. In addition, the AIDS subgroup with pain and substance abuse reported more global symptom distress on the MSAS (F 1, 170 = 20.05, P , 0.001), more psychological distress on the BSI (F 1, 171 = 47.06, P , 0.001), and increased depression (F 1, 171 = 39.05, P , 0.001) and anxiety (F 1, 171 = 23.66, P , 0.001) on the BSI subscales, and more interference in their daily functioning due to pain on the BPI (F 1, 161 = 22.87, P , 0.001). Pain ratings among the AIDS subgroup were also poorer when rating pain at its worst (F 1, 162 = 4.50, P , 0.05), least (F 1, 162 = 20.15, P , 0.001), on average (F 1, 162 = 22.03, P , 0.001), and at the time of assessment (F 1, 161 = 14.00, P , 0.001). Finally, the AIDS group with pain and substance abuse also reported a significantly lower percentage of relief from their current medications (F 1, 156 = 76.14, P , 0.001).
Using the PMI as a measure of presumed adequacy of pain treatment, 132 patients (76.3%) had appropriate treatment and 32 (18.5%) had inadequate treatment. AIDS patients (adequate, n = 41 [56.2%], and inadequate, n = 24 [32.9%]) were significantly more likely to be inadequately medicated than the cancer patients (adequate, n = 91 [91%], and inadequate, n = 8 [8%]) (x 2 = 20.78, P , 0.001).
In the total sample, the most frequent potentially aberrant behaviors were expressing anxiety or depression over recurrent symptoms (n = 64, 37.4%) and hoarding medications (n = 50, 29.1%). A series of chi-square analyses conducted to compare the cancer and AIDS samples revealed significant differences in the prevalence of all the behaviors (at P , 0.05 or greater), except for requesting specific drugs or medications (x 2 = 5.33, NS) and using opioids to treat other symptoms besides pain (x 2 = 1.49, NS) ( Table 3 ). Several of the most aberrant behaviors (ie, performing sex for drugs) could not be compared between groups because the cancer group had zero instances. In addition to exploring the individual potentially aberrant behaviors, a total score was created by summing the number of behaviors identified by each patient. With a possible range of 0 to26 behaviors, the average was 3.4 behaviors for the total sample. A one-way ANOVA showed that the AIDS subgroup (mean = 6.1, median = 5.0, SD = 4.6) engaged in significantly more potentially aberrant behaviors than the cancer group (mean = 1.4, median = 1.0, SD = 1.9) (F 1, 171 = 85.00, P , 0.001).
The prevalence of aberrant drug-related behaviors also varied with the PMI (Table 4 ). There were significant differences between those with inadequate versus adequate treatment in the frequency of 13 of the potentially aberrant behaviors but not among the type of aberrant behavior (ie, whether the individual behaviors were more or less indicative of addiction [see Fig. 1]) . The average number of behaviors also differed significantly between these groups (F 3, 160 = 27.50, P , 0.001). In contrast to this analysis in the total sample, there were no significant associations between the PMI score and the prevalence of aberrant behaviors within the AIDS group or the cancer group, respectively. However, regarding the average number of behaviors between groups mentioned above, a post hoc Bonferroni analysis showed significant differences in the average number of behaviors between the AIDS patients with adequate pain management and the cancer patients with either adequate (mean difference = 4.7, P , 0.001) or inadequate pain management (mean difference = 5.5, P , 0.001). Likewise, a significant difference was seen between the AIDS patients with inadequate pain management and the cancer patients with either adequate (mean difference = 4.9, P , 0.001) or inadequate pain management (mean difference = 5.6, P , 0.001).
To further explore the relationship between pain treatment and aberrant drug-related behaviors, additional analyses evaluated the BPI item asking the percentage of pain relief from the current analgesic regimen. For the cancer group, only the aberrant behavior of drinking alcohol to treat pain was significantly related to a low percentage of pain relief (F 10, 36 = 3.29, P , 0.01). For the AIDS group, behaviors significantly associated with a low percentage of relief included raising the dose of opioids on one's own (F 10, 49 = 2.83, P , 0.01), telling family members that they would use street drugs to relieve pain (F 10, 50 = 2.73, P , 0.01), using more opioids than the physician recommended (F 10, 49 = 2.27, P , 0.05), and using opioids to treat other symptoms (F 10, 49 = 2.08, P , 0.05).
Correlation and Regression Analyses
Multiple regression analyses were conducted on the total sample and each disease subgroup separately. As a first step, study measures that had significant zero-order correlations with the total score of aberrant behaviors were identified. As shown in Table 5 , all of the study measures were significantly correlated to the total number of potentially aberrant behaviors when considering the total sample. Within the cancer sample, only the PMI was not significantly related to the number of potentially aberrant drug-taking behaviors (r = 0.09, NS), while in the AIDS sample, the MCSDS (r = 0.38, P , 0.01) and BPI-Interference Scale (r = 0.29, P , 0.05) were the only two correlates of potentially aberrant drugtaking behaviors.
Given the correlational evidence, all of the study measures were included in the regression analysis for the total sample. In addition, demographic variables of interest (ie, age, gender, ethnicity, education, marital and employment status) were forced into the first iteration of the analysis, and whether the patient had an active SUD was forced in the second iteration before allowing the study measure variables into the equation. Thus, demographic data were entered on the first step, current SUD status was entered on the second step, and the seven study measurements were entered on the third step. Results of the analysis showed that age (R 2 D = 0.20, F 1, 154 = 37.27, P , 0.001) and a current SUD (R 2 D = 0.08, When examining the cancer sample alone, the demographic variables were entered on the first step, followed by the significantly related study measures. Since the cancer sample was now isolated, status of SUD was not entered. Results of the analysis showed that age (R 2 D = 0.09, F 1, 95 = 9.53, P , 0.01), the Global Severity Index of the BSI (R 2 D = 0.12, F 1, 94 = 14.22, P , 0.001), and the MCSDS (R 2 D = 0.05, F 1, 93 = 6.05, P , 0.05) were the only significant predictors of potentially aberrant behaviors. When examining the AIDS sample with the significantly related measures, only the MCSDS (R 2 D = 0.15, F 1, 87 = 10.04, P , 0.01) was a significant predictor of potentially aberrant behaviors.
DISCUSSION
In this prospective study, the prevalence and correlates of aberrant drug-taking behaviors were evaluated in two populations: (1) patients with HIV-related pain and a history of substance abuse and (2) patients with cancer pain and no history of substance abuse. Given the known differences in these groups in the base rates of addiction and drug abuse and the likelihood for undertreatment, 4 these data are likely to reflect a spectrum related to the phenomenology of drugtaking behavior.
This empiric study of drug-taking behaviors is needed to replace anecdotal observations that can be misleading in the medical setting. There is little agreement among physicians about aberrant behaviors beyond viewing illegal behaviors as worrisome. 26 Behaviors considered aberrant by physicians may in fact be common, and their correlates may help practitioners interpret problematic events in the clinical setting. For example, knowledge of the association between a history of illicit drug use and the occurrence of unsupervised opioid dose escalation may help clinicians develop an appropriate response to the latter occurrence in different types of patients with unrelieved pain. Ideally, clinical responses should be guided by information about the actual prevalence and nature of aberrant drug-taking behaviors in distinct medically ill populations. Several important points of interest were uncovered in this study. Patients with AIDS-related pain and histories of substance abuse had higher global distress on both the MSAS and the BSI, higher depression and anxiety scores on the BSI subscales, greater pain-related interference in their daily functioning on the BPI, and a lower percentage of relief from their current medications. AIDS patients with pain and histories of substance abuse also reported more than twice as many examples of aberrant drug-related behaviors per patient as the cancer patients. In the cancer group, the aberrant behavior of drinking alcohol to treat pain was significantly related to a low percentage of pain relief from current analgesic therapy. In the AIDS pain/substance abuse group, a low percentage of pain relief from current analgesic therapy was related to raising the dose of opioids on one's own, telling family members that they would use street drugs to relieve pain, using more opioids than the physician recommended, and using opioids to treat other symptoms. These data indicate that AIDS patients with histories of substance abuse who receive opioid therapy for pain are more symptomatic, have 13 (31.7) 9 (9.9) Expressed concern to family, saying that pain might lead to use of street drugs 9 (28.1) 9 (37.5) more distress, experience more interference from residual pain, and engage in more problematic drug-related behaviors than patients who have no history of drug abuse and receive opioids for cancer pain. These differences likely result from multiple sources, including substance abuse itself, variation in pain treatment practices, and other psychiatric and social problems that are comorbid with addiction. It is telling that the adequacy of analgesia did not affect the type or frequency of aberrant behavior: pain alone is not the driving force behind these behaviors in these complex patients.
There are other differences between the two groups that may bear on the adequacy of pain management and aberrant drug-taking behavior. For instance, we found the AIDS group with pain and substance abuse to be younger, less educated, more likely to be unemployed, and more likely to be male, minority, and single. Among these differences are some known risk factors for receiving inadequate pain therapy (eg, less education, minority group member) and for higher rates of drug abuse (eg, younger, male). These risk factors may combine in a synergistically negative fashion to set in motion aberrant drug-related behaviors.
The present study builds on the extensive literature on the undertreatment of pain in cancer and AIDS. 5, 12, [27] [28] [29] [30] Given the differences in these two populations, it is not surprising that substance abusers with AIDS displayed nearly twice as many aberrant behaviors per patient as the cancer patients. But it is interesting to note that aberrant behaviors are better predicted by demographics, drug abuse history, and psychological distress than by pain variables. Specifically, age and a known SUD had the most predictive impact on the sample as a whole, once again reiterating the notion that addiction is most times a disorder of the young and that past behavior predicts future performance. In addition, the response set of trying to maintain social desirability and a higher degree of symptom distress are keys for identifying aberrant behaviors. It is curious in this patient group that higher degrees of social desirability were associated with more aberrant behaviors. Perhaps patients who abuse drugs are ''proud'' of the ingenuity they employ in their efforts to self-treat their pain or addiction, while also maintaining their clinically oft-cited charm. Another possibility is that patients may have detected the bias of the researchers in trying to document their plight, particularly their need to take pain management into their own hands.
These data suggest that we have come a long way with regard to gross numbers reflecting the adequacy of pain management afforded to the substance-abusing AIDS population, but we clearly have a long way to go. These data certainly suggest improvement since the Breitbart et al 12 study reporting 85% undermedication. In the present study, AIDS patients were still undermedicated compared with cancer patients, but the gap is narrowing. Poor access to palliative care is also reflected in the continued (since Rosenfeld et al 5 ) higher rates of nearly every type of psychosocial distress in the AIDS group. Again, this probably reflects different base rates of these problems in substance abusers (with or without AIDS) compared with cancer patients, though the high rates of distress suggest that their needs go unmet. The contributions of a history of drug abuse, the sociodemographics of disenfranchisement, high rates of psychosocial distress, and poor palliative care continue to complicate the treatment of pain in substance abusers with AIDS.
We attempted to predict aberrant behaviors in this study with an often-used but admittedly very gross measure of adequacy of analgesia, the PMI. The adequacy of analgesia did not affect the total number of behaviors seen in the AIDS group. If this finding is replicated in a future study, it is a blow to those who might argue that the provision of pain relief is a solution to problems of addiction and aberrant behaviors in such patients, suggesting instead that if pain management in addicts does not attend to both sets of needs (pain and addiction), successful outcomes are unlikely. However, the PMI may have particular problems when applied to this population, as it does not take into account the dosage of medication prescribed, and this group of patients is known to have unique pharmacologic needs (ie, for higher, sometimes astronomically high, doses due to tolerance and other physiologic factors 31 ), and patients with adequate PMIs can be grossly undermedicated. On the other hand, arguing against this being a major factor in the present study is the fact that no other pain variables predicted the absolute numbers of aberrant behaviors reported by AIDS patients. Thus, aberrant behaviors seem more linked to substance abuse variables and psychosocial distress than pain/analgesia ones. This finding is reminiscent of those comparing psychosocial distress in gay men and substance abusers with AIDS that pointed to the predictive power of the group of origin over subsequent disease variables. Essentially, that line of research found that distress levels were related to the core group to which a patient belonged (ie, all gay men or all substance abusers) rather than their disease status (ie, either having AIDS or not). [32] [33] [34] Therefore, a parallel notion in the present study is that being a patient with AIDS was an overriding factor for aberrant drug-taking behaviors, whether or not pain was adequately medicated according to the PMI. This study has several limitations. The sampling method was one of convenience. This may induce volunteer bias as well as other unknown forms of bias, as random assignment of patients was not possible. Thus, the results should be taken with caution, and care needs to be taken not to extrapolate the findings to the respective patient populations at large. In addition, the study used a total reliance on self-report methodologies, which is worrisome given the topic of the study and may have led to some social desirability response bias. Further, there was no corroboration from urine toxicology screens or other measurable identifiers, and there is some issue over the adequacy of the PMI as a marker of adequate pain control. Future trials would benefit from more precise terminology and definitions as well as determining a more reliable measure of the adequacy of pain control. Also, it may be beneficial to follow those on opioid therapy by use of independent raters. Overall, this is a necessary venue for continued research and needs to be expanded to the study of populations with a variety of medical illnesses.
